Sugi Predict

Sugi Predict / Compounds / SCHEMBL695370

SCHEMBL695370

SCHEMBL695370

CCS(=O)(=O)N1CCC(N)CC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ TSHR P16473 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ LMNA P02545 3/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ TP53 P04637 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ GNAI3 P08754 2/20 0.39
▸ GNAO1 P09471 2/20 0.39
▸ GNAI1 P63096 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29903895 0.98 KDM4E (0.43) KDM4EPOLBL3MBTL1TSHRGAA
SCHEMBL1516954 0.87 ALDH1A1 (0.50) KDM4EL3MBTL1GAALMNAMAPT
SCHEMBL1564007 0.84 NPC1 (0.45) KDM4ELMNAMAPTALDH1A1ALOX15
SCHEMBL2423436 0.82 ALOX5AP (0.32) KDM4EPOLBL3MBTL1TSHRGAA
SCHEMBL22339879 0.80 SMYD3 (0.40) KDM4ELMNAMAPTALDH1A1ALOX15
SCHEMBL2424805 0.80 JAK2 (0.46) —
SCHEMBL2430904 0.80 LMNA (0.46) KDM4EPOLBL3MBTL1TSHRGAA
SCHEMBL5006783 0.79 ALDH1A1 (0.36) KDM4EPOLBL3MBTL1TSHRGAA
SCHEMBL24474544 0.78 MAPT (0.47) KDM4ELMNAMAPTALDH1A1CYP3A4
SCHEMBL22787352 0.78 LMNA (0.33) KDM4EPOLBL3MBTL1TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233833-B1 NOVEL COMPOUNDS CHIESI FARM SPA (IT) 2019-02-20 — — EP claimed
US-9409870-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2016-08-09 — — US claimed
US-20160168101-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2016-06-16 — — US claimed
EP-1628968-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS MITSUBISHI TANABE PHARMA CORP (JP) 2011-04-06 — — EP claimed
US-20230416271-A1 HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) 2023-12-28 — — US disclosed
US-20230257394-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2023-08-17 — — US disclosed
US-20230257394-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2023-08-17 — — US disclosed
CN-116601155-A Heteroaryl quinazoline compounds as protein kinase inhibitors 成都赛璟生物医药科技有限公司 2023-08-15 — — CN disclosed
CN-116589454-A Aromatic heterocyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-08-15 — — CN disclosed
US-20230174488-A1 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS INSILICO MEDICINE IP LIMITED (HK) 2023-06-08 — — US disclosed
US-20220273659-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO OPERATING COMPANY LLC 2022-09-01 — — US disclosed
WO-2022155941-A1 CDK2 INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2022-07-28 — — WO disclosed
US-20090048256-A1 Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-02-19 — — US disclosed
EP-1951678-A1 PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY Mitsubishi Tanabe Pharma Corporation (JP) 2008-08-06 — — EP disclosed
EP-1878727-A1 2-AMINOQUINAZOLINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-01-16 — — EP disclosed
EP-1846395-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S Astex Therapeutics Limited (GB) 2007-10-24 — — EP disclosed
US-7268150-B2 2-cyano-4-fluoropyrrolidine derivative or its salt YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-11 — — US disclosed
US-7268150-B2 2-cyano-4-fluoropyrrolidine derivative or its salt YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-11 — — US disclosed
WO-2007046550-A1 PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 — — WO disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048256-A1 Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity CNR1, CNR2, OPRD1 KDM4E 2168/4885POLB 4117/4885L3MBTL1 4545/4885
US-20220273659-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 KDM4E 969/4885POLB 1065/4885L3MBTL1 1563/4885
US-20230416271-A1 HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS CDK9, CDK2, CDK6 KDM4E 1039/4885POLB 1296/4885L3MBTL1 2616/4885
US-20160168101-A1 NOVEL COMPOUNDS ELANE, SERPINB1, MPO KDM4E 4462/4885POLB 2021/4885L3MBTL1 3143/4885
US-20230257394-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 KDM4E 325/4885POLB 204/4885L3MBTL1 3688/4885
US-20230174488-A1 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS ACE2, SARS1, ACE KDM4E 896/4885POLB 1258/4885L3MBTL1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.